Bristol Myers Squibb Reports Three-Year Data for Opdualag in Advanced Melanoma

Bristol Myers Squibb today presented three-year overall survival data from the Phase 2/3 RELATIVITY-047 trial evaluating Opdualag (nivolumab plus relatlimab) in patients with previously untreated advanced melanoma. The data showed that Opdualag maintained a progression-free survival benefit over nivolumab alone at three years.